On September 13, 2023 BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "Bioray") reported that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi), indicated for the treatment of CD20-positive diffuse large B-cell lymphoma (DLBCL), was officially approved for marketing by the National Medical Products Administration (NMPA) (Press release, BioRay Pharmaceutical, SEP 13, 2023, View Source [SID1234635150]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In preclinical studies, Anruixi showed stronger antibody-dependent cell-mediated cytotoxicity (ADCC), a larger volume of distribution at steady state, and more sustained clearance of B cells, demonstrating better efficacy compared to other products. Positive results were observed in a randomized, double-blind, active-controlled phase III clinical trial of Anruixi, conducted in 43 study sites nationwide with 487 subjects enrolled. In the head-to-head study with Rituximab, the overall response rate of Anruixi + CHOP was not inferior to that of R-CHOP in patients with early-stage DLBCL, and it had a significantly higher complete response rate vs. R-CHOP. In terms of long-term survival benefits, the Anruixi group achieved better 1-year, 2-year, and 3-year PFS and OS rates compared with the Rituximab group.
As the first domestically developed Class I anti-CD20 drug in China, Anruixi will become BioRay’s next major product following Anruize. Additionally, clinical research is being conducted to explore the use of Anruixi in the field of autoimmune diseases, such as primary immune thrombocytopenia (ITP).
"As the company’s sixth product on the market and its first new drug in the field of tumor immunology，we are particularly grateful for the tremendous efforts made by the clinical researchers who participated in the product’s clinical study, our partners, and our colleagues at Bioray." said Dr. Haibin Wang, CEO of Bioray. "In the future, Bioray will continue to focus on the field of immunology and the unmet medical needs, providing more clinical treatment options, and bringing more medical solutions to patients."